Clinically significant arrhythmias—heart rhythm disturbances severe enough to demand treatment—affected roughly one in every hundred newborns admitted to a neonatal intensive care unit during their first week of life, according to a retrospective single-center study published in BMC Pediatrics. Researchers analyzed the records of 4,126 neonates admitted to the NICU between December 2017 and November 2024 and identified 40 babies, or 0.97 percent, diagnosed with clinically significant arrhythmias in the early neonatal period, defined as the first seven days after birth. Because undetected rhythm abnormalities in newborns can carry substantial risks of mortality and morbidity, the authors argue that recognizing these patterns early is central to improving outcomes.

The study, led by Taner Kasar and Emine Yurdakul Ertürk, drew on a detailed diagnostic workup for each infant, including electrocardiography, Holter monitoring, and echocardiography, alongside clinical signs and symptoms. Supraventricular tachycardia was the most common arrhythmia type, and within that group the most frequent subtype was atrioventricular reentrant tachycardia. On the slow side of the spectrum, the bradyarrhythmia group included non-conducted premature atrial contractions—early atrial beats that fail to reach the ventricles—and complete atrioventricular block, in which electrical signals from the atria no longer reach the ventricles at all.

Two complications stood out in the cohort. Arrhythmia-induced cardiomyopathy, a weakening of the heart muscle driven by sustained abnormal rhythms, was present in eight patients, accounting for 20 percent of the group. Congenital heart disease was identified in five patients, or 12.5 percent. These figures underline a key point from the study: neonatal arrhythmias in this cohort were intertwined with structural heart defects and with secondary damage to the heart muscle itself, which shapes both the urgency of treatment and the long-term outlook.

Initial treatment in the reported cases included vagal maneuvers along with the medications adenosine, amiodarone, and flecainide. The study documents these approaches as the initial management used in this cohort, but it does not establish a preferred escalation sequence, and the retrospective design means treatment assignment reflected each infant’s clinical situation rather than a standardized protocol. The authors report only which treatments were given, not a controlled comparison of their effectiveness.

Outcomes over follow-up were largely favorable. The median follow-up period was 30.5 months, with individual follow-up ranging from 0.25 to 67 months. During that time, supraventricular tachycardia recurred in four cases, and all four achieved rhythm control with antiarrhythmic therapy. One patient in the cohort died due to heart failure. The authors report that the low recurrence and mortality rates among patients without complex congenital heart disease suggest that arrhythmias in the early neonatal period may carry a favorable prognosis when diagnosis is correct and treatment is appropriate.

A specific finding of the study concerns non-conducted premature atrial contractions. The authors emphasize that when these beats cause hemodynamic disturbances—compromising the heart’s ability to maintain adequate blood flow—they can be successfully managed with medical treatment. In such cases, the contractions may lead to clinical conditions requiring early intervention, and appropriate treatment can improve cardiac function.

The study’s design imposes important limits on how broadly its findings can be applied. It was retrospective and conducted at a single center, meaning the 0.97 percent frequency and the distribution of arrhythmia types reflect one institution’s NICU population and referral patterns rather than a population-wide estimate. The small number of affected infants—40 over nearly seven years—also means that subgroup comparisons, such as outcomes between tachyarrhythmia and bradyarrhythmia groups, rest on limited case numbers. The authors note that there is limited evidence overall on the characteristics, frequency, and treatment approaches for arrhythmias in the first week of life, which is precisely the gap this dataset addresses.

Within those constraints, the central message is consistent: early diagnosis and treatment appear central to prognosis in clinically significant neonatal arrhythmias. The combination of low overall mortality in this cohort, complete rhythm control in every case of recurrent supraventricular tachycardia, and successful medical management of hemodynamically significant non-conducted premature atrial contractions supports the authors’ conclusion that prompt recognition, structured diagnostic evaluation with ECG, Holter monitoring, and echocardiography, and appropriate therapy can be associated with a favorable trajectory for most infants without complex congenital heart disease in this single-center experience.

Subject of Research: Frequency, types, management, and outcomes of clinically significant arrhythmias in NICU-admitted neonates during the first week of life

Article Title: Evaluation and management of clinically significant arrhythmias in the early neonatal period: a single-center retrospective study of NICU-admitted neonates

Article References: Kasar, T., & Yurdakul Ertürk, E. (2026). Evaluation and management of clinically significant arrhythmias in the early neonatal period: a single-center retrospective study of NICU-admitted neonates. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07908-x

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07908-x

Keywords: neonatology, arrhythmia, supraventricular tachycardia, NICU, pediatric cardiology, retrospective study, congenital heart disease, bradyarrhythmia, premature atrial contractions, cardiomyopathy, Evaluation, management